Vitamin B3 is a group of structurally related water-soluble compounds that serve as essential precursors to nicotinamide adenine dinucleotide (NAD+) and its reduced form NADH, coenzymes central to hundreds of oxidation-reduction reactions in human metabolism. The three principal forms with distinct biological roles are nicotinic acid (the lipid-modifying form), niacinamide/nicotinamide (the tissue-protective, anti-inflammatory form), and nicotinamide riboside (a newer, more bioavailable NAD+ precursor). Unlike most vitamins, nicotinic acid at pharmacological doses acts more like a drug, having been used as a lipid-modifying agent since the 1950s.

All B3 forms ultimately raise intracellular NAD+ levels, supporting mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. Nicotinic acid additionally acts on GPR109A receptors in adipocytes to inhibit lipolysis, reducing free fatty acid flux to the liver and thereby lowering VLDL/triglyceride synthesis and raising HDL. Niacinamide, by contrast, does not bind GPR109A (and thus causes no flushing) but suppresses inflammatory cytokines and inhibits PARP overactivation, explaining its skin-protective and potentially neuroprotective effects.

Immediate-release nicotinic acid causes the most flushing but has the most cardiovascular outcome trial data. Extended-release niacin (Niaspan) reduces flushing but carries higher hepatotoxicity risk. Niacinamide capsules and topical serums (2–5%) are widely available OTC. Nicotinamide riboside is commercially available as Tru Niagen and similar brands, with multiple published human pharmacokinetic and safety trials.

• Dyslipidemia (High Triglycerides / Low HDL)
• Pellagra / Vitamin B3 Deficiency
• Skin Health & Hyperpigmentation (Topical)
• NAD+ Deficiency / Cellular Energy Support
• Acne (Topical Niacinamide)

• Pellagra (primary prevention via adequate dietary intake—well-established nutritional consensus)
• Recurrence of non-melanoma skin cancer: A randomized controlled trial (Chen et al., 2015, NEJM, n=386) found that oral nicotinamide 500 mg twice daily significantly reduced new actinic keratoses and non-melanoma skin cancers in high-risk patients over 12 months, likely via enhanced DNA repair and reduced UV-induced immunosuppression.

• Beef Liver — One of the highest dietary sources of preformed niacin at approximately 14–17 mg per 3 oz serving, well above the adult RDA of 14–16 mg NE/day; also contains tryptophan for endogenous NAD+ synthesis.
• Chicken Breast — Provides approximately 11–14 mg niacin per 3 oz cooked serving as preformed nicotinic acid/niacinamide, making it one of the most practical and widely consumed dietary sources.
• Tuna (Yellowfin, cooked) — Exceptionally rich in niacin (~22 mg per 3 oz), among the highest of any single food; also a source of tryptophan, which is converted to NAD+ at a ratio of approximately 60:1 (mg tryptophan to mg niacin equivalent).
• Peanuts / Peanut Butter — Provides approximately 4 mg niacin per 1 oz serving (peanuts), making it one of the most significant plant-based sources; also contains tryptophan, though plant-protein tryptophan conversion efficiency is generally lower.
• Brown Rice / Whole Grains — Provides moderate niacin (~3 mg per cup cooked); notably, niacin in many grains is bound as niacytin (bound to polysaccharides), which reduces bioavailability unless treated with alkali (nixtamalization), explaining why corn-dependent diets historically caused pellagra.

• Flushing (warmth, redness, itching of face/chest/arms) — very common with nicotinic acid, dose-dependent, prostaglandin-mediated; mitigated by aspirin pre-treatment, food, or gradual dose titration
• GI disturbance (nausea, vomiting, abdominal discomfort) — particularly with immediate-release nicotinic acid on an empty stomach
• Hepatotoxicity — most significant risk with sustained-release nicotinic acid at doses >2,000 mg/day; rare with immediate-release; requires periodic LFT monitoring
• Hyperuricemia / gout precipitation — nicotinic acid competes with uric acid for renal tubular secretion; dose-dependent risk
• Hyperglycemia / impaired glucose tolerance — high-dose nicotinic acid reduces insulin sensitivity; clinically relevant in pre-diabetic and diabetic patients
• Hypotension / dizziness — related to vasodilatory flushing response, particularly with first doses
• Skin darkening or acanthosis nigricans-like changes — rare, associated with high-dose prolonged use
• Blurred vision / macular edema — rare case reports with high-dose niacin; mechanism not fully established

• Recommended daily: Dietary RDA: 14–16 mg NE/day (adults). Therapeutic uses by form — Nicotinic acid for dyslipidemia: 1,000–3,000 mg/day (titrate slowly starting at 100–250 mg twice daily). Niacinamide for skin/general supplementation: 500–1,500 mg/day orally; 4–5% concentration topically. Nicotinamide riboside (NR) for NAD+ support: 250–1,000 mg/day. Upper tolerable intake level (UL) for nicotinic acid: 35 mg/day (applies to supplements, not food sources).
• Best time of day: Nicotinic acid: take with evening meal to reduce flushing and align with overnight lipid synthesis patterns. Niacinamide oral: any time; with food to minimize GI upset. Topical niacinamide: morning (AM) as part of routine, or twice daily.
• With or without food: Always take nicotinic acid with food to significantly reduce flushing and GI side effects. Niacinamide and NR can be taken with or without food but food improves tolerability. Avoid hot beverages and alcohol around dosing time with nicotinic acid.
• Time to effect: Lipid changes: 4–8 weeks at therapeutic doses. Skin improvements (topical): 4–12 weeks. NAD+ elevation with NR: 2–4 weeks.
• How long to take it: Pellagra treatment: 2–4 weeks of repletion doses under medical supervision. Dyslipidemia: long-term use under physician monitoring with periodic LFTs (every 6–12 months). Topical niacinamide: can be used indefinitely as a skincare ingredient. NR/NAD+ support: no established cycling protocol; continuous use appears safe in trials up to 8–12 weeks with longer safety data still emerging.